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hence more time for follow-up and therapy adjustment, and
physicians who face drug reimbursement constraints.
THE UTILIZATION AND COSTS OF
PRESCRIPTION DRUGS IN A TEXAS MEDICAID
MANAGED CARE PILOT PROGRAM
Johnsrud MT, Lawson KA
University of Texas at Austin, Austin, TX, USA
The state of Texas established a Medicaid Managed Care
Pilot Program in Bexar County on September 1, 1996 for
clients previously in a Fee-For-Service (FFS) plan. Clients
selected either a health maintenance organization (HMO)
or a "gatekeeper" physician through a primary care case
management (PCCM) plan.
OBJECTIVE: This study evaluated the changes in prescrip-
tion utilization and costs when FFS clients entered into ei-
ther an HMO or PCCM health care delivery model.
METHODS: Prescription drug claims were analyzed for
Aid to Families with Dependent Children (AFDC) clients
eligible for both a pre-implementation period (December
1, 1995-May 31, 1996) and a post-implementation pe-
riod (December 1, 1996-May 31, 1997). A total of
59,377 HMO clients and 67,451 PCCM clients were
studied. Three control sites were selected consisting of
Medicaid clients in FFS, HMO, and PCCM plans for
both study periods in other geographical locations across
the state. Changes in the utilization and costs of prescrip-
tions per month were measured for each client between
the pre- and post-implementation periods.
RESULTS: One-way analysis of variance showed that the
mean change in monthly prescription costs per client was
highest between periods for clients in the PCCM experi-
mental group ($4.61, s.d. = $44.63), followed by HMO
clients in the experimental group ($2.10, s.d. = $26.21).
These cost increases were significantly higher than those
in the HMO ($0.68, s.d. = $34.91), PCCM ($1.44, s.d.
= $42.40), and FFS ($1.05, s.d. = 21.86) control groups
(p < 0.001). The percent of prescriptions dispensed as ge-
nerics increased across periods in all groups, except for
the PCCM experimental group.
CONCLUSION: Prescription drug costs may increase
when FFS Medicaid clients enter an HMO or PCCM
health care delivery plan.
POSTMARKETING OUTCOMES STUDIES:
BENEFITS AND RISKS
Garfield FB, Caro JJ
Caro Research, Boston, MA, USA
OBJECTIVE: To consider the benefits, financial risks,
and opportunity costs of large postmarketing outcomes
studies as demonstrated by studies of the statin drugs.
METHODS: Literature review.
RESULTS: Benefits: The studies definitively showed that
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the drugs and lowering lipids were safe and efficacious. The
studies also expanded the indications for the drugs, gener-
ated goodwill in the medical and research communities for
the sponsors, allowed them to include specific claims about
the drugs in their advertisements, generated follow-up stud-
ies, and spawned economic analyses that extended interest
in the drugs in both the medical and lay press and had a ma-
jor impact on the clinicians' use of the drug. Risks: The
studies had a strong coattails effect. Each new study was
beneficial to all the statins as well as the one studied. Eco-
nomic analyses after some of the studies concluded that
although the drugs effectively lowered cholesterol and pre-
vented clinical events, use of the drugs was not cost-
effective. Many studies took a long time, and it often took
even longer for the results to be assimilated, to be put into
perspective, and to influence other researchers and clini-
cians. During that time, the sponsoring companies shoul-
dered opportunity costs as well as the actual costs of the
studies. The risk that one drug company would use another
company's results instead of investing in their own research
did not materialize. All the major pharmaceutical companies
with statins conducted their own postmarketing outcomes
studies.
CONCLUSION: How a company weighs the risks and
benefits of strategic studies may depend on its time per-
spective. In the short term, the risks may outweigh the
benefits. Only those companies that have a longer per-
spective may find it beneficial to undertake a large post-
marketing study.
MGB4
RELATIONSHIP BETWEEN QUALITY OF LIFE,
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The relationship between disease severity, quality of life
(QOL), and resource use in patients with atopic dermati-
tis (AD) has not been well explored in a managed care
population. As the overall lifetime incidence of AD is 15-
20%, this represents a substantial burden to the health-
care system.
OBJECTIVE: To investigate how severity of illness as-
sessed via chart review relates to patient-assessed severity,
QOL, and number of physician encounters.
METHODS: Questionnaires regarding AD severity (e.g.,
mild, moderate, severe) were mailed to 400 participants
identified from the claims database. Adults assessed their
QOL using the Dermatology Life Quality Index (DLQI)
and the Short Form 36 (SF-36), while children used the
Children's Dermatology Life Quality Index (CDLQI). The
number of physician visits for AD over the previous 12-
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month period were determined from a claims database.
Data were analyzed using Pearson correlation coefficients.
RESULTS: Results of the interim analysis in 150 respon-
dents (64 adults, 86 children) indicate that patient-
assessed severity had a stronger correlation with DLQI
(r = 0043, p = 0.0004) and CDLQI (r = 0042, p =
0.0011) than did retrospectively assessed severity (r =
0.39, p = 0.0015 [DLQI); and r = 0.10, P = 0044
[CDLQI)). Among the eight domains reported in the SF-
36, the DLQI showed the strongest correlation with the
mental health domain (r = -0.57, P = 0.0001). Visit
counts were significantly correlated with self-assessed se-
verity for adults (r = 0040) and children (r = 0.32).
CONCLUSIONS: A weaker correlation for QOL and
physician visits was observed with retrospectively as-
sessed severity than with patient-assessed severity. Self-
assessed severity of illness correlated moderately well
with QOL and number of physician encounters.
MGBS
ADHERENCE OF HEALTH CARE WORKERS TO
HEPATITIS B VACCINATION (HBY) POLICY IS
INFLUENCED BY LEADERSHIP
Sutton EL
Department of Defense Pharmacoeconomic Center, Fort Sam
Houston, TX, USA
Although OSHA regulations require that HBV be made
available to health care workers (HCW), the participa-
tion rate with the HBV policy is low. Previous studies ad-
dress characteristics of non-adhering HCW but do not
use this information to subsequently develop organiza-
tional strategies to increase adherence rates.
OBJECTIVE: Determine the vaccination rates of all high-
risk HCW to a HBV policy and to evaluate the effect of
leadership in improving those rates at a military hospital.
METHODS: 118 HCW at high risk for hepatitis B were
categorized by selected variables. Univariate analysis as-
sessed the significance of differences between HBV status
and the selected variables. A conditional probability
model evaluated the response to HBV policy and subse-
quent organizational leadership actions to improve vacci-
nation rates.
RESULTS: Only 61% and 56% of the military and civil-
ian HCW had initiated the HBV series; however, 100%
of the housekeepers completed the series. If a supervisor
had the HBV, the Odds Ratio that the HCW had the
HBV was 8.3 (95% CI 3.3, 21.1). The military HCW
completion rate was increased with passive then active
leadership to 85% then 100%. The civilian HCW com-
pletion rate was increased to 70% then 93%, with pas-
sive then active leadership actions during a six-month fol-
low-up observation period. Surprisingly, directed education
and worksite availability had no effect on the nursing
group. Leading reasons for civilian nurses initially declin-
ing HBV were pregnancy/nursing (36%), needle phobia
(28%), no knowledge of availability (21%), no time
(7%), and no risk perception (7%).
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CONCLUSION: Policy alone will not lead to acceptable
HBV rates among HCW. Acceptable rates are achievable
with both combined passive and active organizational
leadership techniques.
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FORMULARY IMPACT DECISION MODELING IN
HMG-COA REDUCTASE INHIBITORS
Corey R, Sung JCY
Novartis Pharmaceuticals Corp., East Hanover, NJ, USA
According to the NHANES III data, a majority of pa-
tients require 20-30% reduction in their LDL-cholesterol
to achieve their NCEP goal. Fluvastatin, a HMG-CoA re-
ductase inhibitor (statin), has been shown to be both safe
and effective in achieving 20-30% reductions in LDL-
cholesterol, and of all the statins, it has the lowest drug
acquisition cost.
OBJECTIVE: The purpose of this model was to assess the
economic impact of using a two-drug formulary that in-
cludes fluvastatin and another statin, versus a one-statin
formulary.
METHODS: In a hypothetical cohort of 10,000 patients,
a two-drug formulary with fluvasta tin as the statin of
choice for mild to moderate LDL-cholesterol reduction
and another agent for those patients requiring additional
reduction was compared with a one-drug formulary of
atorvastatin, pravastatin, or simvastatin. NHANES III
data was utilized to estimate the percentage of patients
requiring <30% or ;330% LDL-cholesterol reduction.
Doses used in this model were the average daily doses re-
quired for adequate LDL reduction as estimated by 1997
IMS data, and costs of drug therapy using a weighted
AWP. The cost savings was estimated by subtracting the
combined drug acquisition costs of the two statins from
the cost of a single statin prescribed for 100% of the pa-
tients. Sensitivity analyses were also performed on key
parameters of the model.
RESULTS: Based on NHANES III estimation, over 70% of
patients would require a <30% LDL-cholesterol reduction.
A two-drug formulary using fluvastatin was shown to pro-
vide more cost savings than a single-drug formulary using
any of the other agents, with annual cost difference ranging
from $1.2 million to $3 million per 10,000 patients.
CONCLUSIONS: Using formulary modeling, managed
care decision-makers can measure the economic impact of
their statin choice. This model demonstrates the economic
benefit of using fluvastatin in formulary management.
